• Improved disease staging tool for hepatic encephalopathy, approved for use by FDA in phase 3 trials of IV ammonia scavenger (YAQ006) • Dose-response data of oral ammonia scavenger (YAQ007) for prevention of HE recurrence • In vivo demonstration of ammonia scavenger...
• Trial to assess intensive care liver support system across 13 UK centers • Rapid co-primary endpoints measured over 10 and 28 days; readout Q1 2027 • Aims to resolve life-threatening condition and impact survival March 21, 2025
• Ex-Takeda VP Tauhid Ali, Ph.D., with broad leadership and drug development experience becomes Board Director • Seasoned regulatory strategist Darren Rubin becomes VP, Amalive, heading development of the ammonia scavenger OPA, Yaqrit’s phase 3 treatment for hepatic...
• Acute and chronic treatment for hepatic encephalopathy acquired from Mallinckrodt Pharmaceuticals in September 2024 • Extended pre-clinical, clinical and IP package includes FDA and EMA orphan drug and FDA fast track designations February 11,...
